First published on
Dive Brief:
The Association for Molecular Pathology and the Infectious Diseases Society of America are cautioning healthcare providers against using certain data generated by some COVID-19 PCR tests to make patient care decisions.
Some tests generate data known as cycle threshold (Ct) values that have the potential to help determine a patient s prognosis and risk of transmission. But the wide variety of testing procedures in use and lack of a universal threshold are barriers that could result in misinterpretation of results and mismanagement of patients, the groups warned in a blog post.
Separately, the American Clinical Laboratory Association issued a white paper on Thursday recommending that molecular tests that detect SARS-CoV-2 nucleic acid, such as PCR tests, should be prioritized for diagnosing COVID-19 in symptomatic patients.
AdvaMed pushes CMS to implement MCIT final rule without further delay
healthcaredive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healthcaredive.com Daily Mail and Mail on Sunday newspapers.
Judge Dismisses Claims 2016 Rule Medicare Pay Rate Rule for Laboratories was Arbitrary
lawstreetmedia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lawstreetmedia.com Daily Mail and Mail on Sunday newspapers.
Stark, anti-kickback reforms leave labs out of value-based arrangements
modernhealthcare.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernhealthcare.com Daily Mail and Mail on Sunday newspapers.
POLITICO
Get the Prescription Pulse newsletter
Email
Sign Up
By signing up you agree to receive email newsletters or updates from POLITICO and you agree to our privacy policy and terms of service. You can unsubscribe at any time and you can contact us here. This sign-up form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Presented by Coalition for Affordable Prescription Drugs
With Brianna Ehley and Emily Martin.
On Tap Novavax touts the effectiveness of its Covid-19 vaccine. FDA scrutinizes its accelerated drug approval program.
It’s Tuesday, welcome back to Prescription Pulse. Turns out Transportation Secretary Pete Buttigieg is competing with the rest of us for D.C.’s scarce bicycle stock. As always, send tips to Sarah Owermohle ([email protected] or @owermohle) and David Lim ([email protected] or @davidalim).